Nazanin Jamshidi

Nazanin Jamshidi

Auto-generated profile, based on publicly available information

Nazanin Jamshidi

Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2024 in BioImpacts
Verified
Journal Article
Open access
PDF file
NJNazanin Jamshidi
Nazanin Jamshidi
NJNegar Jamshidi
Negar Jamshidi
ACAmir Modarresi Chahardehi
Amir Modarresi Chahardehi
ESElahe Shams
Elahe Shams
VCVahid Chaleshi
Vahid Chaleshi
Pancreatic ductal adenocarcinoma (PDAC) stands as the fourth leading cause of cancer-related deaths, primarily attributable to its resistance to chemotherapy, resulting in a nearly universal fatality rate. Despite the promise exhibited by numerous drugs in preclinical studies, their subsequent failure in clinical trials underscores the inherent limitations of conventional two-dimensional cell culture models commonly employed in early drug screening endeavors. The inadequacies of two-dimensional (2D) models prompted the exploration of three-dimensional (3D) culture systems, which more faithfully recapitulate the native tumor microenvironment. These 3D systems have distinct advantages over 2D models in morphology, proliferation, drug response, and protein expression. Among these 3D platforms, tumor organoids and spheroids, generated through different methodologies, have emerged as next-generation models that closely mirror aspects of pancreatic tumor biology. This comprehensive review scrutinizes pancreatic cancer spheroids' techniques, tissue sources, and applications, offering a nuanced analysis of their advantages and limitations. By comparing these distinct 3D culture systems, researchers gain valuable insights to inform the selection of optimal model designs aligned with their specific experimental objectives. The utilization of these advanced models holds significant promise for enhancing the clinical relevance of both in vitro and in vivo cancer research, thereby contributing to the development of improved therapeutics against pancreatic cancer.

14 May 2026 in Inorganic and Nano-Metal Chemistry
Verified
Journal Article
Closed access
NJNegar Jamshidi
Negar Jamshidi
ACAmir Modarresi Chahardehi
Amir Modarresi Chahardehi
NJNazanin Jamshidi
Nazanin Jamshidi
MCMahta Chehresaz
Mahta Chehresaz
FTFarzaneh Tafvizi
Farzaneh Tafvizi
HAHamid Asadzadeh Aghdaei
Hamid Asadzadeh Aghdaei

15 October 2026 in Beilstein Journal of Nanotechnology
Verified
Journal Article
Open access
PDF file
RAReyhaneh Arefimehr
Reyhaneh Arefimehr
MMMehrad Zibaei Moghadam
Mehrad Zibaei Moghadam
NJNegar Jamshidi
Negar Jamshidi
NJNazanin Jamshidi
Nazanin Jamshidi
Breast cancer remains one of the leading causes of cancer-related mortality worldwide, highlighting the urgent need for more effective and less toxic therapeutic strategies. In the present study, a novel nanotherapeutic platform composed of aqueous Fritillaria persica L . (FP) extract and gemcitabine (Gem)-loaded chitosan (CS) nanoparticles (FP/Gem/CS-NPs) was successfully developed and evaluated against MCF-7 and MDA-MB-231 breast cancer cell lines. Physicochemical characterization demonstrated the successful fabrication of spherical FP/Gem/CS-NPs with a mean hydrodynamic diameter of approximately 69 nm, a polydispersity index (PDI) of 0.500, and a zeta potential of −16.2 mV. The nanoparticles demonstrated high entrapment efficiency (78.41%) and sustained drug release behavior, with nearly 50% of Gem released over 72 h, compared with the rapid burst release of free gemcitabine. Biological evaluations revealed that FP/Gem/CS-NPs exerted significantly enhanced anticancer activity compared with free Gem or FP extract alone. MTT assays demonstrated strong dose- and time-dependent cytotoxicity, with markedly reduced IC 50 values in both MCF-7 and MDA-MB-231 cells following nanoparticle treatment. Flow cytometry and caspase-3/7 analyses confirmed substantial apoptosis induction, particularly in the highly aggressive MDA-MB-231 cells. Gene expression analysis further demonstrated significant upregulation of pro-apoptotic BAX and cell cycle regulator P21, alongside downregulation of anti-apoptotic BCL-2, indicating activation of mitochondrial apoptotic pathways. Moreover, NRF2 expression was elevated, suggesting modulation of oxidative stress responses. Cell cycle analysis revealed prominent G2/M phase arrest in treated cells. Collectively, these findings indicate that FP/Gem/CS-NPs represent a promising synergistic nanotherapeutic system capable of enhancing gemcitabine efficacy while modulating apoptosis, oxidative stress, and cell cycle pathways in breast cancer cells.

3 February 2026 in Applied Biochemistry and Biotechnology
Verified
Journal Article
Closed access
PDF file
STSaghar Zarrin Tarazian
Saghar Zarrin Tarazian
MNMaryam Naseroleslami
Maryam Naseroleslami
VCVahid Chaleshi
Vahid Chaleshi
NJNazanin Jamshidi
Nazanin Jamshidi
NJNegar Jamshidi
Negar Jamshidi
ACAmir Modarresi Chahardehi
Amir Modarresi Chahardehi